The Efficacy of Compression/Ice Gloves/Socks in Patients With UTD1-induced Neuropathy.

Inclusion Criteria13

• Female ，18-75 years;
• Documentation of histologically or cytologically confirmed unresectable locally advanced or metastatic breast cancer;
• The participants is going to receive UTD1 based regimen at least 2 cycles；
• The baseline peripheral sensory neuropathy and peripheral motor neuropathy (CTCAE 5.0) is less than 1 grade;
• ECOG score ≤1;
• Adequate organ and bone marrow function defined as follows within 7 days before enrollment:
• Absolute Neutrophil Count (ANC) ≥1,500/mm 3 (1.5 ×10 9/L), white blood cell count (WBC) ≥3.5×10 9/L, platelets ≥75,000/mm 3 (75×10 9/L), hemoglobin ≥9 g/dL (90 g/L), no blood transfusion and blood products within 14 days, no G-CSF and other hematopoietic stimulation factor within 7 days.
• Serum creatinine ≤1.5 × Upper Limit of Normal (ULN); AST, ALT, ALP exceeding the upper limit of normal but ≤ 2.5 × ULN when no liver metastasis; AST, ALT, ALP exceeding the upper limit of normal but ≤ 5 × ULN when liver metastasis.
• Expected survival time ≥12 weeks;
• No history of serious heart, lung, liver, kidney and other important organ diseases;
• Signed informed consent;
• Good compliance to the protocol;
• Women of childbearing age must already be using reliable contraception, a pregnancy test (blood or urine) is performed within 14 days before enrollment and the result was negative (if positive, pregnancy must be ruled out by ultrasound), and willing to use an appropriate methods of contraception during the trial and for 8 weeks after completion of the trial.